Cargando…

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received one prior platinum-based chemotherapy received 175 or 210 mg m(−...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paz-Ares, L, Ross, H, O'Brien, M, Riviere, A, Gatzemeier, U, Von Pawel, J, Kaukel, E, Freitag, L, Digel, W, Bischoff, H, García-Campelo, R, Iannotti, N, Reiterer, P, Bover, I, Prendiville, J, Eisenfeld, A J, Oldham, F B, Bandstra, B, Singer, J W, Bonomi, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391114/ https://www.ncbi.nlm.nih.gov/pubmed/18475293 http://dx.doi.org/10.1038/sj.bjc.6604372

Ejemplares similares

Procoagulant inhibitory properties of paclitaxel poliglumex
por: Nemunaitis, John, et al.
Publicado: (2010)

Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer–drug conjugate
por: Chipman, Stewart D, et al.
Publicado: (2006)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

Peripheral Neuropathy Caused by Paclitaxel and Docetaxel: An Evaluation and Comparison of Symptoms
por: Tofthagen*, Cindy, et al.
Publicado: (2013)

Role of microRNAs in the resistance of prostate cancer to docetaxel and paclitaxel
por: Kopczyńska, Ewa
Publicado: (2016)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
por: Li, Zhe, et al.
Publicado: (2021)

Silicate Esters of Paclitaxel and Docetaxel: Synthesis, Hydrophobicity, Hydrolytic Stability, Cytotoxicity, and Prodrug Potential
por: Wohl, Adam R., et al.
Publicado: (2014)

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel
por: Rocha, Sandra M., et al.
Publicado: (2023)

Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel
por: Yun, Tianyang, et al.
Publicado: (2015)

Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer
por: Rajappa, Senthil, et al.
Publicado: (2018)

Development of a bayesian toxo-equivalence model between docetaxel and paclitaxel
por: Sigworth, Elizabeth A., et al.
Publicado: (2022)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review
por: Pellegrino, Benedetta, et al.
Publicado: (2017)

Pathologic Response After Weekly Paclitaxel versus Docetaxel in Operable Breast Cancer
por: Bacinschi, Xenia Elena, et al.
Publicado: (2020)

The Endocrine Function of the Human Testis. Volume I
por: Eisenfeld, Arnold J.
Publicado: (1975)

Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports
por: KIMURA, KOSEI, et al.
Publicado: (2013)

A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer
por: Xu, Huixin, et al.
Publicado: (2021)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

Retracted: A Meta-Analysis of the Efficacy of Albumin Paclitaxel versus Docetaxel in the Treatment of Breast Cancer
por: Healthcare Engineering, Journal of
Publicado: (2023)

Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel
por: Sousa-Pimenta, Mário, et al.
Publicado: (2023)

Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective
por: Dranitsaris, George, et al.
Publicado: (2015)

High sensitivity assays for docetaxel and paclitaxel in plasma using solid-phase extraction and high-performance liquid chromatography with UV detection
por: Andersen, Anders, et al.
Publicado: (2006)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
por: De Boer, Richard H., et al.
Publicado: (2012)

A feasibility study on maintenance of docetaxel after paclitaxel-carboplatin chemotherapy in patients with advanced ovarian cancer
por: Isonishi, Seiji, et al.
Publicado: (2013)

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013)

Textbook of Contraceptive Practice
por: Eisenfeld, Arnold
Publicado: (1969)

Physiological Effects of Immunity Against Reproductive Hormones
por: Eisenfeld, Arnold
Publicado: (1977)

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
por: del Muro, X García, et al.
Publicado: (2002)

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
por: Fradet, Y, et al.
Publicado: (2019)

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
por: Wist, E. A., et al.
Publicado: (2012)

Efficacy and Safety of Albumin-Bound Paclitaxel Compared to Docetaxel as Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer
por: Lv, Zhi-Dong, et al.
Publicado: (2022)

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
por: Molife, L Rhoda, et al.
Publicado: (2014)

Nedaplatin or Oxaliplatin Combined with Paclitaxel and Docetaxel as First-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Keqian, et al.
Publicado: (2014)

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2018)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Design and Modeling of Light Emitting Nano-Pixel Structure (LENS) for High Resolution Display (HRD) in a Visible Range
por: Eisenfeld, Tsion, et al.
Publicado: (2020)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck
por: Schell, Amy, et al.
Publicado: (2015)

Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung Cancer
por: Chen, Yi, et al.
Publicado: (2017)

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
por: Xu, Qiaoping, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mpd87qn1rn8l3h7c37i81kka7e